Published in Curr Fungal Infect Rep on December 01, 2011
Cryptococcus gattii infections. Clin Microbiol Rev (2014) 1.55
Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. MBio (2012) 1.28
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother (2015) 1.05
Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog (2015) 1.02
New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS (2013) 0.98
The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front Immunol (2014) 0.94
T-cell reconstitution during murine acquired immunodeficiency syndrome (MAIDS) produces neuroinflammation and mortality in animals harboring opportunistic viral brain infection. J Neuroinflammation (2013) 0.85
Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis. Infect Immun (2013) 0.82
The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum. Curr Opin Infect Dis (2016) 0.78
Regulatory T Cell Induction and Retention in the Lungs Drives Suppression of Detrimental Type 2 Th Cells During Pulmonary Cryptococcal Infection. J Immunol (2015) 0.76
Rim Pathway-Mediated Alterations in the Fungal Cell Wall Influence Immune Recognition and Inflammation. MBio (2017) 0.75
RIPK3/Fas-Associated Death Domain Axis Regulates Pulmonary Immunopathology to Cryptococcal Infection Independent of Necroptosis. Front Immunol (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med (2009) 5.55
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun (1986) 4.91
IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol (2007) 4.54
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91
Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun (1994) 3.46
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med (2010) 2.94
Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis (2008) 2.87
Cryptococcosis. Infect Dis Clin North Am (2006) 2.82
The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol (2002) 2.63
IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol (2007) 2.48
Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr (2009) 2.29
Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol (2005) 2.28
Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis (2010) 2.19
Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol (2000) 2.14
IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol (2005) 2.00
Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol (2001) 1.84
Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect Immun (1989) 1.76
IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol (1997) 1.71
Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun (2009) 1.66
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One (2010) 1.62
The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res (2006) 1.58
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect Immun (2004) 1.42
Role of granulocyte macrophage colony-stimulating factor in host defense against pulmonary Cryptococcus neoformans infection during murine allergic bronchopulmonary mycosis. Am J Pathol (2007) 1.31
Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect Immun (1997) 1.28
Cryptococcus neoformans: a sugar-coated killer with designer genes. FEMS Immunol Med Microbiol (2005) 1.28
IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am J Pathol (2009) 1.27
Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med (2002) 1.26
Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS One (2011) 1.25
Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol (2002) 1.14
IL-17/Th17 in anti-fungal immunity: what's new? Eur J Immunol (2009) 1.11
Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection. Infect Immun (2010) 1.10
Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun (2001) 1.08
Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infect Immun (2008) 1.07
Mannose binding lectin plays a crucial role in innate immunity against yeast by enhanced complement activation and enhanced uptake of polymorphonuclear cells. BMC Microbiol (2008) 1.01
Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo. Infect Immun (2005) 0.94
The capsular polysaccharides of Cryptococcus neoformans activate normal CD4(+) T cells in a dominant Th2 pattern. J Immunol (2001) 0.92
Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. Am J Hematol (1998) 0.90
A single dose of granulocyte-macrophage colony-stimulating factor induces systemic interleukin-8 release and neutrophil activation in healthy volunteers. Blood (1996) 0.79
Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis (2010) 4.08
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis (2010) 2.86
Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA (2004) 2.70
Diagnostic performance of rapid diagnostic tests versus blood smears for malaria in US clinical practice. Clin Infect Dis (2009) 1.91
Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr (2012) 1.85
Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One (2013) 1.84
Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr (2013) 1.71
Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest (2005) 1.57
Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome. Biomark Med (2008) 1.55
Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis (2014) 1.55
Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med (2012) 1.53
Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol (2010) 1.32
Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. MBio (2012) 1.28
Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep (2013) 1.21
Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis (2013) 1.19
Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda. PLoS One (2012) 1.16
The Cryptococcus neoformans transcriptome at the site of human meningitis. MBio (2014) 1.11
Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis (2013) 1.11
Acute heart failure from lyme carditis. Circ Heart Fail (2012) 1.09
Methods of rapid diagnosis for the etiology of meningitis in adults. Biomark Med (2014) 1.03
Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother (2011) 1.01
Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis (2013) 1.00
Impact of global health residency training on medical knowledge of immigrant health. Am J Trop Med Hyg (2011) 0.98
The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS (2010) 0.96
Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia. PLoS One (2013) 0.95
Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL. Clin Infect Dis (2012) 0.95
Significantly improved analytical sensitivity of lateral flow immunoassays by using thermal contrast. Angew Chem Int Ed Engl (2012) 0.93
Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis (2013) 0.93
Financial implications of refugee malaria: the impact of pre-departure presumptive treatment with anti-malarial drugs. Am J Trop Med Hyg (2007) 0.92
Role of quantitative CSF microscopy to predict culture status and outcome in HIV-associated cryptococcal meningitis in a Brazilian cohort. Diagn Microbiol Infect Dis (2012) 0.83
Accuracy of pima point-of-care CD4 analyzer in routine use in public health clinics in Uganda. J Acquir Immune Defic Syndr (2013) 0.80
AIDS-related mycoses: the way forward. Trends Microbiol (2014) 0.80
Nosocomial drug-resistant bacteremia in 2 cohorts with cryptococcal meningitis, Africa. Emerg Infect Dis (2014) 0.79
A case for treating high hepatitis B DNA levels before starting HIV therapy. AIDS (2006) 0.79
The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum. Curr Opin Infect Dis (2016) 0.78
Thermal Contrast Amplification Reader Yielding 8-Fold Analytical Improvement for Disease Detection with Lateral Flow Assays. Anal Chem (2016) 0.77
Safety, censoring, and intent-to-treat analysis: dangers to generalizability. Clin Infect Dis (2010) 0.76
The trials of the returning traveler: ciprofloxacin failure in enteric fever. Minn Med (2008) 0.75
Brief Report: Virologic Monitoring Can Be a Cost-Effective Strategy to Diagnose Treatment Failure on First-Line ART. J Acquir Immune Defic Syndr (2016) 0.75
Hypereosinophilic syndrome and mepolizumab. N Engl J Med (2008) 0.75
Implementation and Operational Research: Impact of Nurse-Targeted Care on HIV Outcomes Among Immunocompromised Persons: A Before-After Study in Uganda. J Acquir Immune Defic Syndr (2016) 0.75
Migrants, detainees, and misconceptions. Lancet (2009) 0.75
Antiretroviral therapy after cryptococcal meningitis. N Engl J Med (2014) 0.75
Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal Meningitis. J Acquir Immune Defic Syndr (2016) 0.75
The CSF immune response in HIV-1-associated cryptococcal meningitis: macrophage activation, correlates of disease severity and effect of antiretroviral therapy. J Acquir Immune Defic Syndr (2017) 0.75
The role of nanoparticle design in determining analytical performance of lateral flow immunoassays. Nano Lett (2017) 0.75